Passion for Innovation. Compassion for Patients.™
Daiichi Sankyo Europe GmbH
Dear User,
This website provides you with information only for healthcare professionals. According to the drug
promotion code, we are only able to allow healthcare professionals like physicians and pharmacists to have
full access to our website. To visit our page please login.
European News
Daiichi Sankyo and DarwinHealth Enter Exclusive Research Collaboration for Novel Cancer Target Initiative
Daiichi Sankyo
2018-04-05 11:48:16
Daiichi Sankyo and DarwinHealth Enter Exclusive Research Collaboration for Novel Cancer Target Initiative
Daiichi Sankyo’s HER2-Targeting Antibody Drug Conjugate DS-8201 Receives SAKIGAKE Designation for Gastric Cancer from Japan MHLW
Daiichi Sankyo
2018-04-05 11:49:37
Daiichi Sankyo’s HER2-Targeting Antibody Drug Conjugate DS-8201 Receives SAKIGAKE Designation for Gastric
Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with HER2-Expressing Advanced Colorectal Cancer
Daiichi Sankyo
2018-03-07 15:41:22
Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with HER2-Expressing Advanced Colorectal Cancer
Daiichi Sankyo Initiates Phase 1 Study of DS-1062 in Patients with Advanced Non-Small Cell Lung Cancer
Daiichi Sankyo
2018-02-22 19:00:01
Daiichi Sankyo Initiates Phase 1 Study of DS-1062 in Patients with Advanced Non-Small Cell Lung Cancer
Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Daiichi Sankyo
2018-02-06 16:00:01
Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung
Daiichi Sankyo Reports on Practical Implications of Advances and Challenges in Oral Anticoagulation
Daiichi Sankyo
2018-02-05 16:00:01
Daiichi Sankyo Reports on Practical Implications of Advances and Challenges in Oral Anticoagulation
Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Gastric Cancer at ASCO 2018 Gastrointestinal Cancers Symposium
Daiichi Sankyo
2018-01-18 16:45:01
Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Gastric Cancer at ASCO 2018
Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
Daiichi Sankyo
2017-12-15 16:45:01
Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated
Once-Daily, Oral LIXIANA®▼ (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CANCER Study
Daiichi Sankyo
2017-12-12 16:45:01
Once-Daily, Oral LIXIANA®▼ (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CANCER Study
Daiichi Sankyo Presents Phase 1 Data for EZH1/2 Dual Inhibitor DS-3201 in Patients with Non-Hodgkin Lymphomas at the 59th Annual Meeting of the American Society of Hematology
Daiichi Sankyo
2017-12-12 16:45:01
Daiichi Sankyo Presents Phase 1 Data for EZH1/2 Dual Inhibitor DS-3201 in Patients with Non-Hodgkin Lymphomas
More Stories
